Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer
10.1016/j.gpb.2014.10.003
- Author:
Rose C MAIMON
;
Kostyanovskaya ELINA
;
Huang Stephanie R
- Keywords:
Cisplatin;
Non-small cell lung cancer;
Biomarker;
Nucleotide excision repair;
Copper transport;
Glutathione S-transferase
- From:
Genomics, Proteomics & Bioinformatics
2014;(5):198-209
- CountryChina
- Language:Chinese
-
Abstract:
Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a wide variety of cancers with varying degrees of success. In particular, cisplatin has been used to treat late stage non-small cell lung cancer (NSCLC) as the standard of care. However, therapeutic outcomes vary from patient to patient. Considerable efforts have been invested to identify biomark-ers that can be used to predict cisplatin sensitivity in NSCLC. Here we reviewed current evidence for cisplatin sensitivity biomarkers in NSCLC. We focused on several key pathways, including nucleotide excision repair, drug transport and metabolism. Both expression and germline DNA variation were evaluated in these key pathways. Current evidence suggests that cisplatin-based treatment could be improved by the use of these biomarkers.
